MACULAR HYPOTROPHY AFTER INTERNAL LIMITING MEMBRANE REMOVAL FOR DIABETIC MACULAR EDEMA
Authors:
- Mario R. RomanoMRMario R. Romano
- Vito RomanoVito Romano
- Jose L. Vallejo-GarciaJVJose L. Vallejo-Garcia
- Riccardo VinciguerraRVRiccardo Vinciguerra
- Mary RomanoMRMary Romano
- Matteo CeredaMCMatteo Cereda
- Martina AngiMAMartina Angi
- Xavier ValldeperasXVXavier Valldeperas
- Ciro CostagliolaCCCiro Costagliola
- Paolo VinciguerraPVPaolo Vinciguerra
- 1 June 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 34 (6) , 1182-1189
Abstract
To compare the anatomic and functional effects of three different approaches to nontractional diabetic macular edema. Retrospective comparative study. Sixty eyes of 60 patients diagnosed with cystoid diabetic macular edema and treated with 1.25 mg/mL intravitreal bevacizumab (Group A), laser photocoagulation (Group B), or vitrectomy with inner limiting membrane peeling (Group C) were included in the study. Changes in number of Early Treatment Diabetic Retinopathy Study letters, central macular thickness, largest diameter of the intraretinal cysts (IC), and choroidal thickness were investigated. Analyses were performed during follow-up visits at Months 1, 3, 6, 9, and 12. Visual acuity only significantly improved in Group A at the last follow-up (P = 0.004). Central macular thickness significantly decreased in every group throughout the follow-up period. Differences in central macular thickness between Groups A and B (P < 0.01), A and C (P < 0.01), and B and C (P < 0.01) were significant. Intraretinal cysts also significantly decreased in each group throughout the follow-up period. Differences in IC size between Groups A and B (P = 0.8), A and C (P = 0.1), and B and C (P = 0.1) were not significant. Choroidal thickness did not undergo any significant change in any group throughout the follow-up period. A significant correlation was also found in Group A between best-corrected visual acuity at month 12 and baseline central macular thickness (R = 0.3; P = 0.006), and in Group B between postoperative best-corrected visual acuity at month 12 and baseline IC size (R = 0.8; P < 0.01, negatively correlated at 92.4%). According to our retrospective data, diabetic macular edema with intraretinal cysts larger than 390 μm should not be treated with vitrectomy with ILM peeling, because this may induce subfoveal atrophy, defined as the "Floor Effect," and subsequent visual deterioration.Keywords
This publication has 46 references indexed in Scilit:
- RETINA REJUVENATION THERAPY FOR DIABETIC MACULAR EDEMARetina, 2013
- A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular EdemaArchives of Ophthalmology (1950), 2012
- CHOROIDAL IMAGING USING SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHYRetina, 2012
- Histopathologic analysis of the internal limiting membrane surgically peeled from eyes with diffuse diabetic macular edemaJapanese Journal of Ophthalmology, 2012
- CHOROIDAL THICKNESS IN PATIENTS WITH DIABETIC RETINOPATHY ANALYZED BY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHYRetina, 2012
- Significance of Outer Blood–Retina Barrier Breakdown in Diabetes and IschemiaInvestigative Ophthalmology & Visual Science, 2011
- Optical Coherence Tomography May Be Used to Predict Visual Acuity in Patients with Macular EdemaInvestigative Ophthalmology & Visual Science, 2011
- Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2011
- Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulationBritish Journal of Ophthalmology, 2009
- Pathophysiology of Diabetic Macular EdemaInternational Ophthalmology Clinics, 2009